Thoratec price target raised to $49 from $40 at Barrington

theflyonthewall.com

Barrington reiterates its Outperform rating on Thoratec and raised its price target on shares to $49, citing the company's Q3 results and a CMS decision on BTT eligible patients that the firm views as favorable for Thoratec.

Rates

View Comments (0)